27364
document
Coenzyme Q10 and exercise training in chronic heart failure . AIMS There is evidence that plasma coenzyme Q ( 10 ) ( CoQ ( 10 ) ) levels decrease in patients with advanced chronic heart failure ( CHF ) . However , it is not known whether oral CoQ ( 10 ) supplementation may improve cardiocirculatory efficiency and endothelial function in patients with CHF . METHODS AND RESULTS We studied 23 patients in NYHA class II and III ( 20 men , three women , mean age 59+/-9 years ) with stable CHF secondary to ischaemic heart disease [ ejection fraction 37+/-7 % ] , using a double-blind , placebo-controlled cross-over design . Patients were assigned to each of the following treatments : oral CoQ ( 10 ) ( 100 mg tid ) , CoQ ( 10 ) plus supervised exercise training ( ET ) ( 60 % of peak VO ( 2 ) , five times a week ) , placebo , and placebo plus ET . Each phase lasted 4 weeks . Both peak VO ( 2 ) and endothelium-dependent dilation of the brachial artery ( EDDBA ) improved significantly after CoQ ( 10 ) and after ET as compared with placebo . CoQ ( 10 ) main effect was : peak VO ( 2 ) +9 % , EDDBA +38 % , systolic wall thickening score index ( SWTI ) -12 % ; ET produced comparable effects . CoQ ( 10 ) supplementation resulted in a four-fold increase in plasma CoQ ( 10 ) level , whereas the combination with ET further increased it . No side effects were reported with CoQ ( 10 ) . CONCLUSIONS Oral CoQ ( 10 ) improves functional capacity , endothelial function , and LV contractility in CHF without any side effects . The combination of CoQ ( 10 ) and ET resulted in higher plasma CoQ ( 10 ) levels and more pronounced effects on all the abovementioned parameters . However , significant synergistic effect of CoQ ( 10 ) with ET was observed only for peak SWTI suggesting that ET amplifies the already described effect of CoQ ( 10 ) on contractility of dysfunctional myocardium .
27365
Intervention_Pharmacological
Coenzyme Q10
27366
Intervention_Pharmacological
( CoQ ( 10 ) )
27367
Intervention_Pharmacological
CoQ ( 10 )
27368
Intervention_Pharmacological
oral CoQ ( 10 ) ( 100 mg tid ) ,
27369
Intervention_Physical
supervised exercise training ( ET )
27370
Intervention_Control
placebo
27371
Intervention_Control
placebo plus ET
27372
Intervention_Pharmacological
CoQ ( 10 )
27373
Intervention_Physical
ET
27374
Intervention_Control
placebo
27375
Intervention_Pharmacological
CoQ ( 10 )
27376
Intervention_Physical
ET
27377
Intervention_Pharmacological
CoQ ( 10 )
27378
Intervention_Pharmacological
CoQ ( 10 )
27379
Intervention_Physical
ET
27380
Intervention_Pharmacological
CoQ ( 10 ) .
27381
Intervention_Pharmacological
Oral CoQ ( 10 )
27382
Intervention_Pharmacological
CoQ ( 10 )
27383
Intervention_Physical
ET
27384
Intervention_Pharmacological
CoQ ( 10 )
27385
Intervention_Pharmacological
CoQ ( 10 )
27386
Intervention_Physical
ET
27387
Intervention_Physical
ET
27388
Intervention_Pharmacological
CoQ ( 10 )
27389
Outcome_Physical
coenzyme Q ( 10 ) ( CoQ ( 10 ) ) levels
27390
Outcome_Physical
cardiocirculatory efficiency and endothelial function
27391
Outcome_Physical
peak VO ( 2 ) and endothelium-dependent dilation of the brachial artery ( EDDBA )
27392
Outcome_Physical
peak VO
27393
Outcome_Physical
EDDBA
27394
Outcome_Physical
systolic wall thickening score index ( SWTI )
27395
Outcome_Physical
plasma CoQ ( 10 ) level
27396
Outcome_Physical
functional capacity
27397
Outcome_Physical
endothelial function
27398
Outcome_Physical
LV contractility
27399
Outcome_Adverse-effects
side effects
27400
Outcome_Physical
SWTI
27401
Outcome_Physical
contractility of dysfunctional myocardium
27402
Participant_Condition
chronic heart failure
27403
Participant_Condition
patients with advanced chronic heart failure ( CHF ) .
27404
Participant_Condition
CHF
27405
Participant_Sample-size
23
27406
Participant_Sample-size
20
27407
Participant_Sex
men
27408
Participant_Sample-size
three
27409
Participant_Sex
women
27410
Participant_Age
59+/-9 years
27411
Participant_Condition
CHF